IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...
In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...
Alpha Tau Medical (DRTS) pioneers alpha emitter-based targeted radiation therapy, aiming for highly localized tumor ...
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel ...
Compass Pathways (CMPS) stock rises as the company posts new late-stage trial data for its psychedelic therapy COMP360 ...
After spending nearly Rs 6,800 crore and more than two decades, Wockhardt has achieved what no Indian pharmaceutical company ...
The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results